UNICYCIVE THERAPEUTICS INC (UNCY) Fundamental Analysis & Valuation

NASDAQ:UNCY • US90466Y2028

6.95 USD
-0.1 (-1.42%)
At close: Mar 10, 2026
6.94 USD
-0.01 (-0.14%)
After Hours: 3/10/2026, 4:53:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This UNCY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to UNCY. UNCY was compared to 519 industry peers in the Biotechnology industry. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability. UNCY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. UNCY Profitability Analysis

1.1 Basic Checks

  • UNCY had negative earnings in the past year.
  • UNCY had a negative operating cash flow in the past year.
  • UNCY had negative earnings in each of the past 5 years.
  • In the past 5 years UNCY always reported negative operating cash flow.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of UNCY (-105.21%) is worse than 76.69% of its industry peers.
  • Looking at the Return On Equity, with a value of -192.09%, UNCY is doing worse than 66.86% of the companies in the same industry.
Industry RankSector Rank
ROA -105.21%
ROE -192.09%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. UNCY Health Analysis

2.1 Basic Checks

  • UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • UNCY has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, UNCY has more shares outstanding
  • There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • UNCY has an Altman-Z score of -1.01. This is a bad value and indicates that UNCY is not financially healthy and even has some risk of bankruptcy.
  • UNCY has a Altman-Z score (-1.01) which is comparable to the rest of the industry.
  • UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.01
ROIC/WACCN/A
WACC8.79%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 2.18 indicates that UNCY has no problem at all paying its short term obligations.
  • UNCY has a worse Current ratio (2.18) than 75.14% of its industry peers.
  • A Quick Ratio of 2.18 indicates that UNCY has no problem at all paying its short term obligations.
  • The Quick ratio of UNCY (2.18) is worse than 72.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.18
Quick Ratio 2.18
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. UNCY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.65% over the past year.
  • The Revenue for UNCY has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)61.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • UNCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.11% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.78%
EPS Next 2Y36.89%
EPS Next 3Y51.04%
EPS Next 5Y21.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. UNCY Valuation Analysis

4.1 Price/Earnings Ratio

  • UNCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UNCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • UNCY's earnings are expected to grow with 51.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.89%
EPS Next 3Y51.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UNCY Dividend Analysis

5.1 Amount

  • UNCY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNCY Fundamentals: All Metrics, Ratios and Statistics

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (3/10/2026, 4:53:59 PM)

After market: 6.94 -0.01 (-0.14%)

6.95

-0.1 (-1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-26
Inst Owners39.47%
Inst Owner Change29.96%
Ins Owners2.93%
Ins Owner Change0%
Market Cap149.36M
Revenue(TTM)N/A
Net Income(TTM)-31.56M
Analysts82.86
Price Target47.43 (582.45%)
Short Float %8.78%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.93%
Min EPS beat(2)31.11%
Max EPS beat(2)56.75%
EPS beat(4)3
Avg EPS beat(4)-6.92%
Min EPS beat(4)-183.22%
Max EPS beat(4)67.68%
EPS beat(8)4
Avg EPS beat(8)-40.65%
EPS beat(12)5
Avg EPS beat(12)-44.53%
EPS beat(16)6
Avg EPS beat(16)-39.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-47.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.09
P/tB 9.09
EV/EBITDA N/A
EPS(TTM)-3.95
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -105.21%
ROE -192.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 251.85%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.18
Quick Ratio 2.18
Altman-Z -1.01
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34%
EPS Next Y82.78%
EPS Next 2Y36.89%
EPS Next 3Y51.04%
EPS Next 5Y21.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-73.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.69%
OCF growth 3YN/A
OCF growth 5YN/A

UNICYCIVE THERAPEUTICS INC / UNCY FAQ

What is the fundamental rating for UNCY stock?

ChartMill assigns a fundamental rating of 2 / 10 to UNCY.


What is the valuation status for UNCY stock?

ChartMill assigns a valuation rating of 1 / 10 to UNICYCIVE THERAPEUTICS INC (UNCY). This can be considered as Overvalued.


How profitable is UNICYCIVE THERAPEUTICS INC (UNCY) stock?

UNICYCIVE THERAPEUTICS INC (UNCY) has a profitability rating of 0 / 10.


Is the dividend of UNICYCIVE THERAPEUTICS INC sustainable?

The dividend rating of UNICYCIVE THERAPEUTICS INC (UNCY) is 0 / 10 and the dividend payout ratio is 0%.